Multi-omics and machine learning-driven CD8+ T cell heterogeneity score for head and neck squamous cell carcinoma
The heterogeneity of head and neck squamous cell carcinoma (HNSCC) poses a significant challenge to treatment, underscoring the urgent need for more precise and personalized therapeutic approaches. CD8+ T cells, integral components of the tumor immune microenvironment, have emerged as key targets fo...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Molecular Therapy: Nucleic Acids |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253124003007 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823856795383234560 |
|---|---|
| author | Di He Zhan Yang Tian Zhang Yaxian Luo Lianjie Peng Jiatao Yan Tao Qiu Jingyu Zhang Luying Qin Zhichao Liu Mouyuan Sun |
| author_facet | Di He Zhan Yang Tian Zhang Yaxian Luo Lianjie Peng Jiatao Yan Tao Qiu Jingyu Zhang Luying Qin Zhichao Liu Mouyuan Sun |
| author_sort | Di He |
| collection | DOAJ |
| description | The heterogeneity of head and neck squamous cell carcinoma (HNSCC) poses a significant challenge to treatment, underscoring the urgent need for more precise and personalized therapeutic approaches. CD8+ T cells, integral components of the tumor immune microenvironment, have emerged as key targets for immunotherapy. Our research has established a correlation between a decrease in CD8+ T cell score and a poor clinical prognosis, highlighting the prognostic value of this biomarker. By analyzing the gene expression related to CD8+ T cells, we have differentiated HNSCC into cold and hot tumor subtypes, uncovering disparities in clinical prognosis and responses to immunotherapy. Utilizing eight machine learning methods, we identified the key gene OLR1. Single-cell analysis of HNSCC tissues and peripheral blood, along with spatial transcriptome analysis, revealed that OLR1 predominantly functions in macrophages, modulating the immune microenvironment of HNSCC. The expression level of OLR1 may serve as a predictive marker for immunotherapy responses. Moreover, drug sensitivity analysis and molecular docking studies have indicated that simvastatin and pazopanib are potential inhibitors of OLR1. These findings suggest that simvastatin and pazopanib could open up innovative potential therapeutic avenues for individuals with HNSCC. |
| format | Article |
| id | doaj-art-035980dbabe742daaef81c32f0224342 |
| institution | Kabale University |
| issn | 2162-2531 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Therapy: Nucleic Acids |
| spelling | doaj-art-035980dbabe742daaef81c32f02243422025-02-12T05:30:59ZengElsevierMolecular Therapy: Nucleic Acids2162-25312025-03-01361102413Multi-omics and machine learning-driven CD8+ T cell heterogeneity score for head and neck squamous cell carcinomaDi He0Zhan Yang1Tian Zhang2Yaxian Luo3Lianjie Peng4Jiatao Yan5Tao Qiu6Jingyu Zhang7Luying Qin8Zhichao Liu9Mouyuan Sun10Department of Oral and Maxillofacial Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, ChinaStomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Hangzhou, Zhejiang Province, ChinaDepartment of Oral and Maxillofacial Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, ChinaStomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Hangzhou, Zhejiang Province, ChinaStomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Hangzhou, Zhejiang Province, ChinaStomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Hangzhou, Zhejiang Province, ChinaStomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Hangzhou, Zhejiang Province, ChinaStomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Hangzhou, Zhejiang Province, ChinaStomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Hangzhou, Zhejiang Province, ChinaStomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Hangzhou, Zhejiang Province, ChinaStomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Hangzhou, Zhejiang Province, China; Corresponding author: Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Hangzhou, Zhejiang Province, China.The heterogeneity of head and neck squamous cell carcinoma (HNSCC) poses a significant challenge to treatment, underscoring the urgent need for more precise and personalized therapeutic approaches. CD8+ T cells, integral components of the tumor immune microenvironment, have emerged as key targets for immunotherapy. Our research has established a correlation between a decrease in CD8+ T cell score and a poor clinical prognosis, highlighting the prognostic value of this biomarker. By analyzing the gene expression related to CD8+ T cells, we have differentiated HNSCC into cold and hot tumor subtypes, uncovering disparities in clinical prognosis and responses to immunotherapy. Utilizing eight machine learning methods, we identified the key gene OLR1. Single-cell analysis of HNSCC tissues and peripheral blood, along with spatial transcriptome analysis, revealed that OLR1 predominantly functions in macrophages, modulating the immune microenvironment of HNSCC. The expression level of OLR1 may serve as a predictive marker for immunotherapy responses. Moreover, drug sensitivity analysis and molecular docking studies have indicated that simvastatin and pazopanib are potential inhibitors of OLR1. These findings suggest that simvastatin and pazopanib could open up innovative potential therapeutic avenues for individuals with HNSCC.http://www.sciencedirect.com/science/article/pii/S2162253124003007MT: BioinformaticsHNSCCCD8+ T cellsmulti-omicsmachine learningprecision therapy |
| spellingShingle | Di He Zhan Yang Tian Zhang Yaxian Luo Lianjie Peng Jiatao Yan Tao Qiu Jingyu Zhang Luying Qin Zhichao Liu Mouyuan Sun Multi-omics and machine learning-driven CD8+ T cell heterogeneity score for head and neck squamous cell carcinoma Molecular Therapy: Nucleic Acids MT: Bioinformatics HNSCC CD8+ T cells multi-omics machine learning precision therapy |
| title | Multi-omics and machine learning-driven CD8+ T cell heterogeneity score for head and neck squamous cell carcinoma |
| title_full | Multi-omics and machine learning-driven CD8+ T cell heterogeneity score for head and neck squamous cell carcinoma |
| title_fullStr | Multi-omics and machine learning-driven CD8+ T cell heterogeneity score for head and neck squamous cell carcinoma |
| title_full_unstemmed | Multi-omics and machine learning-driven CD8+ T cell heterogeneity score for head and neck squamous cell carcinoma |
| title_short | Multi-omics and machine learning-driven CD8+ T cell heterogeneity score for head and neck squamous cell carcinoma |
| title_sort | multi omics and machine learning driven cd8 t cell heterogeneity score for head and neck squamous cell carcinoma |
| topic | MT: Bioinformatics HNSCC CD8+ T cells multi-omics machine learning precision therapy |
| url | http://www.sciencedirect.com/science/article/pii/S2162253124003007 |
| work_keys_str_mv | AT dihe multiomicsandmachinelearningdrivencd8tcellheterogeneityscoreforheadandnecksquamouscellcarcinoma AT zhanyang multiomicsandmachinelearningdrivencd8tcellheterogeneityscoreforheadandnecksquamouscellcarcinoma AT tianzhang multiomicsandmachinelearningdrivencd8tcellheterogeneityscoreforheadandnecksquamouscellcarcinoma AT yaxianluo multiomicsandmachinelearningdrivencd8tcellheterogeneityscoreforheadandnecksquamouscellcarcinoma AT lianjiepeng multiomicsandmachinelearningdrivencd8tcellheterogeneityscoreforheadandnecksquamouscellcarcinoma AT jiataoyan multiomicsandmachinelearningdrivencd8tcellheterogeneityscoreforheadandnecksquamouscellcarcinoma AT taoqiu multiomicsandmachinelearningdrivencd8tcellheterogeneityscoreforheadandnecksquamouscellcarcinoma AT jingyuzhang multiomicsandmachinelearningdrivencd8tcellheterogeneityscoreforheadandnecksquamouscellcarcinoma AT luyingqin multiomicsandmachinelearningdrivencd8tcellheterogeneityscoreforheadandnecksquamouscellcarcinoma AT zhichaoliu multiomicsandmachinelearningdrivencd8tcellheterogeneityscoreforheadandnecksquamouscellcarcinoma AT mouyuansun multiomicsandmachinelearningdrivencd8tcellheterogeneityscoreforheadandnecksquamouscellcarcinoma |